Loading…

SI-BONE, Inc.SIBNCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 95
Mkt cap
$1.06B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$22.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-24.4 pp
WACC 8.2%
Hurdle
n/a
no reverse DCF
Next earnings
103 days
1 Mar 2027
Close · USD$23.54
1D+1.6%
1W-5.6%
1M+14.6%
3M+20.8%
6M+58.8%
YTD+19.4%
1Y+31.4%
ATR %4.8%
Beta0.77
52w lowhigh9.2% off high

What SI-BONE does

Employees: 376

SI-BONE at a glance

Size SI-BONE (SIBN) is a United States Health Care company (Medical Specialties) with a market value of $1.06B, the 2193rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $23.54 on 18 Nov 2026.

Performance Over six months the shares gained 58.8%, against -8.9% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.

Growth Revenue grew 14.0% over the last twelve months (peer median +10.0%); the operating margin is -7.6% (peer median 17.4%).

Valuation It trades at 4.3× enterprise value to sales against a peer median of 4.0× (10th most expensive of 20).

Capital Return on invested capital runs 24.4 points below its cost of capital (8.2% WACC).

Short interest Short interest is 10.0% of the free float (30 Oct 2026).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515017521 May 202621 Aug 202618 Nov 2026SIBN 159Peer median 92
Six months, rebased to 100: SI-BONE against the median of its 20 peers (local-currency closes).

SI-BONE financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$221M$201M$167M$139M$106M
Revenue growth—+20%+20%+31%—
Gross profit$175M$160M$132M$109M$90.7M
EBITDA-$10.1M-$16.6M-$30.9M-$41.5M-$56.2M
Net income-$13.7M-$18.9M-$30.9M-$43.3M-$61.3M
Free cash flow-$4.19M-$9.09M-$22.9M-$26.5M-$51.2M
Capital expenditure$10.3M$8.41M$10.5M$7.80M$9.51M
Total debt$42.8M$36.7M$37.5M$39.0M$39.4M

Quarterly statements and history in the cockpit →

SI-BONE competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%688622301101IRMDIART214150ATECCSTLEUZ6000553010216523DRTS300685300206300406CBLL6881613001437730SIBN6-month return →1-month return →
Up and to the right = strong over both horizons. SI-BONE is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×25×50×75×688622301101IRMDIART214150ATECCSTL6000553010216523300406CBLL688161300143SIBNRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. SI-BONE is the large dot.

SI-BONE competitors and peer comparison

How SI-BONE compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SI-BONE against its 20 peers (data as of 18 Nov 2026)
MeasureSIBNPeer medianRank in peer set
1-month return+14.6%-6.0%3rd highest of 21
6-month return+58.8%-8.9%2nd highest of 20
Distance from 52-week high-9.2%-29.4%highest of 21
Revenue growth (TTM)+14.0%+10.0%7th highest of 19
Operating margin-7.6%17.4%4th lowest of 20
EV / Sales4.3×4.0×10th most expensive of 20
ROIC minus cost of capital-24.4 pp+3.2 pp2nd lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
SI-BONE SIBNUnited States$1.06B+59%+14%-8%4.3×n/an/a
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%85.0×n/an/a
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%6.3×8.8%+8.8%
IRadimed IRMDUnited States$1.05B-9%+11%32%11.1×18.5%+21.5%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%1.7×5.9%+3.6%
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%4.0×-9.2%+34.5%
Freenome FRNMUnited States$1.08Bn/an/a36%4.7×n/an/a
Alphatec ATECUnited States$1.10B-14%+15%-3%1.9×n/an/a
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%2.1×57.7%+40.6%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%2.7×7.7%+12.1%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%3.0×n/an/a
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%11.1×50.8%+8.6%
PHC 6523.TJapan$1.02B+34%+3%8%0.9×-4.0%+3.5%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%4.7×4.9%+10.4%
Edan Instruments 300206.SZChina$1.00B-19%+14%17%2.5×6.9%-2.9%
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%5.8×1.7%+9.9%
Ceribell CBLLUnited States$995M+42%+31%-70%8.3×n/an/a
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%4.7×11.3%-3.5%
INKON Life Technology 300143.SZChina$985M-23%+22%12%3.1×10.7%+12.9%
Mani 7730.TJapan$965M-7%+10%30%3.9×3.3%+13.9%

Questions

Which companies are SI-BONE's closest peers?
The cockpit's peer set: Guangzhou Hexin Instrument (688622.SS), Mingyue Optical Lens (301101.SZ), IRadimed (IRMD), Integra LifeSciences (IART), CLASSYS (214150.KS), Freenome (FRNM), Alphatec (ATEC), Castle Biosciences (CSTL).
Is SI-BONE expensive compared with its peers?
On ev / sales it trades at 4.3× against a peer median of 4.0×, 10th most expensive of 20 in its peer set.
How has SI-BONE stock performed?
Over six months to 18 Nov 2026 the shares returned +58.8% against -8.9% for the median peer; over one year +31.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.